Patents by Inventor David J. Harris
David J. Harris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11957338Abstract: Stapling assemblies for use with a surgical stapler are provided. In one exemplary embodiment, the stapling assembly includes a cartridge having a plurality of staples disposed therein and a non-fibrous adjunct formed of at least one fused bioabsorbable polymer and configured to be releasably retained on the cartridge. Adjunct systems for use with a surgical stapler are also provided. Surgical end effectors using the stapling assemblies are also provided. Methods for manufacturing stapling assemblies and using the same are also provided.Type: GrantFiled: July 28, 2022Date of Patent: April 16, 2024Assignee: Cilag GmbH InternationalInventors: Jason L. Harris, Michael J. Vendely, Frederick E. Shelton, IV, Austin Bridges, Peyton Hopson, Jackie Donners, Hardik Kabaria, Farhad Javid, David Arthur Kelly, Elliott Baker, Stephen J. Peter, Xinyu Gu, Gina Michelle Policastro, Sharon Chen
-
Patent number: 11931110Abstract: A surgical instrument is disclosed comprising a control system and a strain gage circuit. The operation of the control system is modifiable by an input from the strain gage circuit.Type: GrantFiled: December 14, 2018Date of Patent: March 19, 2024Assignee: Cilag GmbH InternationalInventors: Frederick E. Shelton, IV, Michael J. Vendely, Jason L. Harris, Gregory J. Bakos, David C. Yates
-
Publication number: 20190240252Abstract: The present invention relates to crosslinked polyamine particles and/or pharmaceutical compositions comprising, at least in part, crosslinked polyamine particles and aggregates of such particles (including cured aggregates of crosslinked polyamine particles). The compositions may be in the form of tablets comprising, for example, particles larger than 500 ?m, and used for treating patients, for example, patients with hyperphosphatemia.Type: ApplicationFiled: February 4, 2019Publication date: August 8, 2019Inventors: Stephen Randall HOLMES-FARLEY, David J. HARRIS, Steven C. POLOMOSCANIK, Adnan SALAMEH, Bruce SHUTTS, Richard SILVA, Pradeep K. DHAL, Lynne SOLE
-
Patent number: 9945192Abstract: A hydraulic draw-works comprises several hydraulic cylinders of mixed orientation, such that some hydraulic cylinders actuate upwards and some hydraulic cylinders actuate downwards. These cylinders are connected by a plurality of braces mounted along a guide rail, and the drill head is mounted on a carriage along the guide rail and actuated by the upwards-oriented cylinders. The use of mixed orientation cylinders allows the effective vertical stroke length required to raise and lower the drill head to be halved. In a preferred embodiment, through-rod porting of the downwards-oriented cylinders supplies hydraulic fluid to the remainder through a manifold, and digitally controlled directional valves allow precise control of the drill head.Type: GrantFiled: May 6, 2015Date of Patent: April 17, 2018Assignee: Viola Group LimitedInventors: Wiley T. Brice, David J. Harris, Graham A. Hamshaw
-
Publication number: 20180093981Abstract: A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-?, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 13, 2017Publication date: April 5, 2018Inventors: Craig Siegel, Cecilia M. Bastos, David J. Harris, Angeles Dios, Edward Lee, Richard Silva, Lisa M. Cuff, Mikaela Levine, Cassandra A. Celatka, Frederic Vinick, Thomas H. Jozefiak, Yibin Xiang, John Kane, Junkai Liao
-
Patent number: 9745294Abstract: A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-?, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 16, 2014Date of Patent: August 29, 2017Assignee: Genzyme CorporationInventors: Craig Siegel, Cecilia M. Bastos, David J. Harris, Angeles Dios, Edward Lee, Richard Silva, Lisa M. Cuff, Mikaela Levine, Cassandra A. Celatka, Frederic Vinick, Thomas H. Jozefiak, Yibin Xiang, John Kane, Junkai Liao
-
Patent number: 9744153Abstract: A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 21, 2016Date of Patent: August 29, 2017Assignee: Genzyme CorporationInventors: Craig Siegel, Cecilia M. Bastos, David J. Harris, Angeles Dios, Edward Lee, Richard Silva, Lisa M. Cuff, Mikaela Levine, Cassandra A. Celatka, Thomas H. Jozefiak, Frederic Vinick, Yibin Xiang, John Kane, Junkai Liao
-
Publication number: 20170152347Abstract: Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.Type: ApplicationFiled: November 9, 2016Publication date: June 1, 2017Inventors: Pradeep K. DHAL, David J. HARRIS, Stephen Randall HOLMES-FARLEY, Chad C. HUVAL, Vitaly NIVOROZHKIN, Bruce SHUTTS
-
Publication number: 20160338996Abstract: A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: January 21, 2016Publication date: November 24, 2016Inventors: Craig Siegel, Cecilia M. Bastos, David J. Harris, Angeles Dios, Edward Lee, Richard Silva, Lisa M. Cuff, Mikaela Levine, Cassandra A. Celatka, Thomas H. Jozefiak, Frederic Vinick, Yibin Xiang, John Kane, Junkai Liao
-
Publication number: 20160158275Abstract: The present invention relates to crosslinked polyamine particles and/or pharmaceutical compositions comprising, at least in part, crosslinked polyamine particles and aggregates of such particles (including cured aggregates of crosslinked polyamine particles). The compositions may be in the form of tablets comprising, for example, particles larger than 500 ?m, and used for treating patients, for example, patients with hyperphosphatemia.Type: ApplicationFiled: December 14, 2015Publication date: June 9, 2016Inventors: Stephen Randall HOLMES-FARLEY, David J. HARRIS, Steven C. POLOMOSCANIK, Adnan SALAMEH, Bruce SHUTTS, Richard SILVA, Pradeep K. DHAL, Lynne SOLE
-
Patent number: 9272996Abstract: A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 27, 2012Date of Patent: March 1, 2016Assignee: Genzyme CorporationInventors: Craig Siegel, Cecilia M. Bastos, David J. Harris, Angeles Dios, Edward Lee, Richard Silva, Lisa M. Cuff, Mikaela Levine, Cassandra A. Celatka, Thomas H. Jozefiak, Frederic Vinick, Yibin Xiang, John Kane, Junkai Liao
-
Publication number: 20160032666Abstract: A hydraulic draw-works comprises several hydraulic cylinders of mixed orientation, such that some hydraulic cylinders actuate upwards and some hydraulic cylinders actuate downwards. These cylinders are connected by a plurality of braces mounted along a guide rail, and the drill head is mounted on a carriage along the guide rail and actuated by the upwards-oriented cylinders. The use of mixed orientation cylinders allows the effective vertical stroke length required to raise and lower the drill head to be halved. In a preferred embodiment, through-rod porting of the downwards-oriented cylinders supplies hydraulic fluid to the remainder through a manifold, and digitally controlled directional valves allow precise control of the drill head.Type: ApplicationFiled: May 6, 2015Publication date: February 4, 2016Inventors: Wiley T. Brice, David J. Harris, Graham A. Hamshaw
-
Publication number: 20150321996Abstract: Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.Type: ApplicationFiled: May 21, 2015Publication date: November 12, 2015Inventors: Pradeep K. DHAL, David J. HARRIS, Stephen Randall HOLMES-FARLEY, Chad C. HUVAL, Vitaly NIVOROZHKIN, Bruce SHUTTS
-
Publication number: 20150225393Abstract: A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-?, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 16, 2014Publication date: August 13, 2015Inventors: Craig Siegel, Cecilia M. Bastos, David J. Harris, Angeles Dios, Edward Lee, Richard Silva, Lisa M. Cuff, Mikaela Levine, Cassandra A. Celatka, Frederic Vinick, Thomas H. Jozefiak, Yibin Xiang, John Kane, Junkai Liao
-
Patent number: 9066972Abstract: Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.Type: GrantFiled: April 24, 2014Date of Patent: June 30, 2015Assignee: Genzyme CorporationInventors: Pradeep K. Dhal, David J. Harris, Stephen Randall Holmes-Farley, Chad C. Huval, Vitaly Nivorozhkin, Bruce Shutts
-
Publication number: 20150094379Abstract: Amine compounds, amine polymers, crosslinked amine polymers and pharmaceutical compositions comprising the same may include polyhydroxy-containing cores that may be substituted with amine groups and may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans.Type: ApplicationFiled: November 24, 2014Publication date: April 2, 2015Inventors: Christopher COOPER, Pradeep K. DHAL, Rayomand GIMI, David J. HARRIS, Stephen Randall HOLMES-FARLEY, Chad C. HUVAL, Edward R. LEE
-
Patent number: 8940776Abstract: A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-?, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 27, 2012Date of Patent: January 27, 2015Assignee: Genzyme CorporationInventors: Craig Siegel, Cecilia M. Bastos, David J. Harris, Angeles Dios, Edward Lee, Richard Silva, Lisa M. Cuff, Mikaela Levine, Cassandra A. Celatka, Frederic Vinick, Thomas H. Jozefiak, Yibin Xiang, John Kane, Junkai Liao
-
Patent number: 8900560Abstract: Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.Type: GrantFiled: March 22, 2013Date of Patent: December 2, 2014Assignee: Genzyme CorporationInventors: Pradeep K. Dhal, David J. Harris, Stephen Randall Holmes-Farley, Chad C. Huval, Vitaly Nivorozhkin, Bruce Shutts
-
Publication number: 20140322319Abstract: The present invention relates to crosslinked polyamine particles and/or pharmaceutical compositions comprising, at least in part, crosslinked polyamine particles and aggregates of such particles (including cured aggregates of crosslinked polyamine particles). The compositions may be in the form of tablets comprising, for example, particles larger than 500 ?m particles and used for treating patients, for example, patients with hyperphosphatemia.Type: ApplicationFiled: April 17, 2014Publication date: October 30, 2014Applicant: GENZYME CORPORATIONInventors: Stephen Randall Holmes-Farley, David J. HARRIS, Steven C. POLOMOSCANIK, Adnan SALAMEH, Bruce SHUTTS, Richard SILVA, Pradeep K. DHAL, Lynne SOLE
-
Publication number: 20140235724Abstract: Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.Type: ApplicationFiled: April 24, 2014Publication date: August 21, 2014Applicant: GENZYME CORPORATIONInventors: Pradeep K. DHAL, David J. HARRIS, Stephen Randall HOLMES-FARLEY, Chad C. HUVAL, Vitaly NIVOROZHKIN, Bruce SHUTTS